JP2023551559A5 - - Google Patents

Info

Publication number
JP2023551559A5
JP2023551559A5 JP2023533838A JP2023533838A JP2023551559A5 JP 2023551559 A5 JP2023551559 A5 JP 2023551559A5 JP 2023533838 A JP2023533838 A JP 2023533838A JP 2023533838 A JP2023533838 A JP 2023533838A JP 2023551559 A5 JP2023551559 A5 JP 2023551559A5
Authority
JP
Japan
Prior art keywords
combination
aforementioned
antibody
day cycle
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023533838A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023551559A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/084133 external-priority patent/WO2022117799A2/en
Publication of JP2023551559A publication Critical patent/JP2023551559A/ja
Publication of JP2023551559A5 publication Critical patent/JP2023551559A5/ja
Pending legal-status Critical Current

Links

JP2023533838A 2020-12-04 2021-12-03 抗cd19併用療法 Pending JP2023551559A (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
EP20211862 2020-12-04
EP20211862.6 2020-12-04
EP21158806 2021-02-23
EP21158806.6 2021-02-23
EP21163696.4 2021-03-19
EP21163696 2021-03-19
EP21172671.6 2021-05-07
EP21172671 2021-05-07
EP21177336 2021-06-02
EP21177336.1 2021-06-02
EP21205447 2021-10-29
EP21205447.2 2021-10-29
PCT/EP2021/084133 WO2022117799A2 (en) 2020-12-04 2021-12-03 Anti-cd19 combination therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026073819A Division JP2026133433A (ja) 2020-12-04 2026-04-27 抗cd19併用療法

Publications (2)

Publication Number Publication Date
JP2023551559A JP2023551559A (ja) 2023-12-08
JP2023551559A5 true JP2023551559A5 (cg-RX-API-DMAC7.html) 2024-12-11

Family

ID=78821967

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023533838A Pending JP2023551559A (ja) 2020-12-04 2021-12-03 抗cd19併用療法

Country Status (12)

Country Link
US (1) US20220184208A1 (cg-RX-API-DMAC7.html)
EP (1) EP4255480A2 (cg-RX-API-DMAC7.html)
JP (1) JP2023551559A (cg-RX-API-DMAC7.html)
KR (1) KR20230131464A (cg-RX-API-DMAC7.html)
AU (1) AU2021391623A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023010885A2 (cg-RX-API-DMAC7.html)
CA (1) CA3204063A1 (cg-RX-API-DMAC7.html)
CL (2) CL2023001581A1 (cg-RX-API-DMAC7.html)
IL (1) IL303384A (cg-RX-API-DMAC7.html)
MX (1) MX2023006538A (cg-RX-API-DMAC7.html)
TW (1) TW202237184A (cg-RX-API-DMAC7.html)
WO (1) WO2022117799A2 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016311136B2 (en) 2015-08-21 2022-02-17 Incyte Corporation Combinations and uses thereof
ES2981046T3 (es) 2016-05-30 2024-10-07 Incyte Corp Métodos para predecir el beneficio terapéutico de una terapia anti-CD19 en pacientes
SMT202100317T1 (it) 2016-06-27 2021-07-12 Morphosys Ag Formulazioni di anticorpi anti-cd19
WO2018078123A1 (en) 2016-10-28 2018-05-03 Morphosys Ag Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
WO2021084062A1 (en) * 2019-10-31 2021-05-06 Morphosys Ag Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma
US20230357392A1 (en) * 2021-12-22 2023-11-09 Morphosys Ag Treatment Paradigm for an Anti-CD19 Antibody Therapy
AU2023285109A1 (en) * 2022-06-10 2024-12-12 Incyte Corporation Combination therapy comprising sirp alpha fusion protein and anti-cd19 antibody for treatment of cancer
WO2023245106A1 (en) 2022-06-16 2023-12-21 Abbvie Biotherapeutics Inc. Anti-cd19 antibody drug conjugates
WO2024037594A1 (en) * 2022-08-19 2024-02-22 Beijing Innocare Pharma Tech Co., Ltd. Combination treatment with orelabrutinib and tafasitamab

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ,インコーポレイティド 人工抗体ポリペプチド
JP4733635B2 (ja) 2003-07-31 2011-07-27 イミューノメディクス、インコーポレイテッド 抗cd19抗体
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
WO2007002223A2 (en) 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
AU2006332155B2 (en) 2005-12-30 2013-01-10 Cancer Research Technology Limited Anti-CD19 antibodies with reduced immunogenicity
RS53263B (sr) 2006-08-14 2014-08-29 Xencor Inc. Optimizovana antitela usmerena na cd19
US8323653B2 (en) 2006-09-08 2012-12-04 Medimmune, Llc Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
CA2693053C (en) 2007-05-30 2021-01-05 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
CN101903403B (zh) 2007-10-19 2016-03-16 西雅图基因公司 Cd19结合剂及其应用
CA2753158A1 (en) 2009-02-23 2010-08-26 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to cd19 and their uses
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
EP2409993A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
EP3018145B1 (en) * 2010-10-27 2018-04-04 Amgen Research (Munich) GmbH Means and methods for treating dlbcl
EP2524929A1 (en) 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
ES2981046T3 (es) * 2016-05-30 2024-10-07 Incyte Corp Métodos para predecir el beneficio terapéutico de una terapia anti-CD19 en pacientes
EP3487525A4 (en) * 2016-07-22 2020-03-18 Seattle Genetics, Inc. COMBINATION THERAPY WITH CD19-ADC AND RCHP
CN114206346A (zh) * 2019-05-03 2022-03-18 凯德药业股份有限公司 施用嵌合抗原受体免疫疗法的方法

Similar Documents

Publication Publication Date Title
JP2014114288A5 (cg-RX-API-DMAC7.html)
JP2014533279A5 (cg-RX-API-DMAC7.html)
JP2022531408A5 (cg-RX-API-DMAC7.html)
JP2020515577A5 (cg-RX-API-DMAC7.html)
KR20240151809A (ko) Fcrn 길항제를 사용하여 근염을 치료하는 방법
EP4512421A1 (en) Drug combination of anti-tim-3 antibody and anti-pd-1 antibody
JP2025500411A5 (cg-RX-API-DMAC7.html)
JP2022541591A5 (cg-RX-API-DMAC7.html)
JP2024540435A5 (cg-RX-API-DMAC7.html)
JP2023546503A5 (cg-RX-API-DMAC7.html)
TW202207976A (zh) 使用免疫檢查點抑制劑抗體治療癌症之方法和組合
IL324054A (en) Pan-elr+ cxc chemokine antibodies for the treatment of hidradenitis suppurativa
JP2024521105A5 (cg-RX-API-DMAC7.html)
CN115957321A (zh) 一种抗her2抗体在制备治疗癌症的药物中的用途
JP2023546504A5 (cg-RX-API-DMAC7.html)
CN112955148B (zh) Cdk4/6抑制剂联合免疫治疗在制备治疗淋巴瘤的药物中的用途
JP2022549218A5 (cg-RX-API-DMAC7.html)
JP2022547061A5 (cg-RX-API-DMAC7.html)
JP2023551519A5 (cg-RX-API-DMAC7.html)
JP2022521773A5 (cg-RX-API-DMAC7.html)
JP2025526402A5 (cg-RX-API-DMAC7.html)
JP3973360B2 (ja) 関節リウマチまたは皮膚疾患の処置に使用するためのcd25結合分子
CA3215919A1 (en) Treatment for systemic lupus erythematosus using anti-baffr antibodies
CN112543637B (zh) 伊立替康联合免疫检查点抑制剂和5-fu在制备治疗肿瘤疾病的药物中的用途
IL311796A (en) Anti-galectin-9 antibodies and their therapeutic uses